Companion Diagnostics & Biomarkers 2017


The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers 2017 . This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.

Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner.

Companion Diagnostics & Biomarkers 2017 you will provide valued information about doing partnership and commercialize CDx tests with pharmaceutical and biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.

We sincerely hope you are able to join us for this year’s meeting and be part of a new paradigm of precision medicine at the Companion Diagnostics & Biomarkers 2017



  • Learn the recent advances and future perspectives in Companion Diagnostics & Biomarkers
  • Understand the key aspects & challenges of Clinical Biomarker development & qualification Solutions for clinical development of precision therapies
  • Regulatory considerations for Next Generation Sequencing (NGS)
  • Main barriers to progression of precision medicine in drug development
  • The Role of In Vitro Diagnostics in Successful Precision Medicine Market Access
  • Options for biomarker based patient stratification in NON-ONCOLOGY clinical development Key trends in targeted and immuno-oncology companion diagnostics
  • Overcoming challenges in the global commercialization of novel biomarkers Diagnostic Strategies for Cancer Immune Therapies
  • Strategic Partnerships for CDx – Challenges and Opportunities



The BioTech Pharma Summit (EPM Group) are exclusive events designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed mem- bers of academic and government institutions.
Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

  • Companion Diagnostics
  • Molecular Diagnostics
  • Personalized Healthcare
  • Clinical Development
  • Regulatory Affairs
  • Molecular Diagnostics
  • Biomarkers
  • Medical Sciences
  • Experimental Medicine
  • Translational Medicine
  • Immunology
  • Genomics
  • Insurers
  • Patient Advocates
  • Payers
  • Market Access
  • Medical Sciences
  • Commercialisation
  • Oncology
  • Non-oncology
  • Rare Diseases
  • Drug Development
  • Research
Christopher Ung
Chief Business Officer
Dr. Martina Kaufmann
Managing Director
Dr. Jakob Gjørret
Managing Director
Dr. Jürgen Doppke
Director Business Development Diagnostics Partnering
Birgitte Booij
Vice President Product and Business development
Robert Hawkins
Cancer Research UK Professor
Stefan Müllner
General Manager & Partner
Morteza Minaee
Vice President of Regulatory Affairs
Alfred Hansel
Jeffrey Jones
Executive Vice President, Commercial Operations
Austin Speier
Vice President, Emerging Technologies
Harry Glorikian
CEO, Sr. Executive, Board Director
Nick Zhang
Chairman and CEO
Dr. Paul Whittaker
Vice President, Discovery Research
Ali Ardakani
Managing Director
Henrik Winther
Senior Vice President, Precision Diagnostics
Susanne Munksted
Susanne Munksted, Global Commercial Director, CDx Commercial Management
Eric Faulkner
Vice President, Precision and Transformative Technology Solutions
Paul Docherty PhD
Relationship and Alliance Management
Gary Gustavsen
Partner, Personalized Medicine
Rohit Nambisan
SVP Product Strategy & Partner Integration; Product Advisor
Event Details